Literature DB >> 2842093

Effects of interleukin 2 and large envelope glycoprotein (gp 120) of human immunodeficiency virus (HIV) on lymphocyte proliferative responses to cytomegalovirus.

J Krowka1, D Stites, J Mills, H Hollander, T McHugh, M Busch, L Wilhelm, L Blackwood.   

Abstract

Lymphocytes from many HIV-infected asymptomatic individuals or patients with AIDS-related conditions (ARC) and from all AIDS patients were unable to proliferate in vitro in response to UV-inactivated cytomegalovirus (CMV). The addition of recombinant IL2 (rIL2) restored proliferative responses of lymphocytes from most HIV-infected asymptomatic individuals and ARC patients to levels similar to those of HIV-seronegative (HIV-) CMV-seropositive (CMV+) individuals. In contrast, rIL2 augmented CMV-specific lymphocyte proliferation of only 33% (6/18) of AIDS patients. Proliferative responses to CMV with or without rIL2 did not correlate well with the levels of CD4+ lymphocytes, HIV antigen levels or ratios of CD4+ and CD8+ lymphocytes. Proliferative responses to CMV were inhibited by relatively high concentrations (greater than or equal to 10 micrograms/ml) of recombinant HIV envelope glycoprotein (rgp120) and this immunosuppression was completely overcome by rIL2. These results indicate that defects in antigen-driven lymphocyte responses of HIV-infected individuals are not simply the result of reduced numbers of CD4+ lymphocytes but are influenced by defects in IL2 pathways and by immunosuppressive effects of HIV gp120.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2842093      PMCID: PMC1541530     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Long term culture of tumour-specific cytotoxic T cells.

Authors:  S Gillis; K A Smith
Journal:  Nature       Date:  1977-07-14       Impact factor: 49.962

2.  The effects of human immunodeficiency virus recombinant envelope glycoprotein on immune cell functions in vitro.

Authors:  M R Shalaby; J F Krowka; T J Gregory; S E Hirabayashi; S M McCabe; D S Kaufman; D P Stites; A J Ammann
Journal:  Cell Immunol       Date:  1987-11       Impact factor: 4.868

3.  Surface molecules involved in self-recognition and T cell activation in the autologous mixed lymphocyte reaction.

Authors:  P L Romain; S F Schlossman; E L Reinherz
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

4.  Partial restoration of impaired interleukin-2 production and Tac antigen (putative interleukin-2 receptor) expression in patients with acquired immune deficiency syndrome by isoprinosine treatment in vitro.

Authors:  K Y Tsang; H H Fudenberg; G M Galbraith; R P Donnelly; L R Bishop; W R Koopmann
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

5.  Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes.

Authors:  D Klatzmann; F Barré-Sinoussi; M T Nugeyre; C Danquet; E Vilmer; C Griscelli; F Brun-Veziret; C Rouzioux; J C Gluckman; J C Chermann
Journal:  Science       Date:  1984-07-06       Impact factor: 47.728

6.  Cell-mediated immunity to cytomegalovirus (CMV) and herpes simplex virus (HSV) antigens in the acquired immune deficiency syndrome: interleukin-1 and interleukin-2 modify in vitro responses.

Authors:  J F Sheridan; L Aurelian; A D Donnenberg; T C Quinn
Journal:  J Clin Immunol       Date:  1984-07       Impact factor: 8.317

7.  The acquired immunodeficiency syndrome.

Authors:  M S Gottlieb; J E Groopman; W M Weinstein; J L Fahey; R Detels
Journal:  Ann Intern Med       Date:  1983-08       Impact factor: 25.391

8.  National case-control study of Kaposi's sarcoma and Pneumocystis carinii pneumonia in homosexual men: Part 2. Laboratory results.

Authors:  M F Rogers; D M Morens; J A Stewart; R M Kaminski; T J Spira; P M Feorino; S A Larsen; D P Francis; M Wilson; L Kaufman
Journal:  Ann Intern Med       Date:  1983-08       Impact factor: 25.391

9.  Viral inhibition of lymphocyte mitogenesis: interference with the synthesis of functionally active T cell growth factor (TCGF) activity and reversal of inhibition by the addition of same.

Authors:  M A Wainberg; S Vydelingum; R G Margolese
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

10.  Possible involvement of the OKT4 molecule in T cell recognition of class II HLA antigens. Evidence from studies of cytotoxic T lymphocytes specific for SB antigens.

Authors:  W E Biddison; P E Rao; M A Talle; G Goldstein; S Shaw
Journal:  J Exp Med       Date:  1982-10-01       Impact factor: 14.307

View more
  8 in total

1.  Inhibitory activity of HIV envelope gp120 dominates over its antigenicity for human T cells.

Authors:  F Manca; L Walker; A Newell; F Celada; J A Habeshaw; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

2.  Simultaneous detection of antibodies to cytomegalovirus and herpes simplex virus by using flow cytometry and a microsphere-based fluorescence immunoassay.

Authors:  T M McHugh; R C Miner; L H Logan; D P Stites
Journal:  J Clin Microbiol       Date:  1988-10       Impact factor: 5.948

3.  Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro.

Authors:  J F Krowka; D P Stites; S Jain; K S Steimer; C George-Nascimento; A Gyenes; P J Barr; H Hollander; A R Moss; J M Homsy
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

4.  Immune responses to fractionated cytomegalovirus (CMV) antigens after HIV infection. Loss of cellular and humoral reactivity to antigens recognized by HIV-, CMV+ individuals.

Authors:  P J Converse; T E Fehniger; A Ehrnst; O Strannegård; S Britton
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

Review 5.  Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions.

Authors:  N Chirmule; S Pahwa
Journal:  Microbiol Rev       Date:  1996-06

Review 6.  Abnormalities in host defense associated with HIV infection.

Authors:  James M Beck
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

7.  Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens.

Authors:  A D Kelleher; M Roggensack; S Emery; A Carr; M A French; D A Cooper
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

8.  Heterogeneous effects of exogenous IL-2 on HIV-specific cell-mediated immunity (CMI).

Authors:  S J Bell; D A Cooper; B E Kemp; R R Doherty; R Penny
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.